vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Legacy Education Inc. (LGCY). Click either name above to swap in a different company.
Legacy Education Inc. is the larger business by last-quarter revenue ($19.2M vs $18.7M, roughly 1.0× CytomX Therapeutics, Inc.). Legacy Education Inc. runs the higher net margin — 10.6% vs -0.8%, a 11.5% gap on every dollar of revenue. On growth, Legacy Education Inc. posted the faster year-over-year revenue change (40.7% vs -25.7%). Legacy Education Inc. produced more free cash flow last quarter ($512.7K vs $-15.8M).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Legacy Education Inc. is a professional educational service provider focused on financial literacy, real estate investment, entrepreneurship, and personal wealth management training programs. It mainly serves individual learners across North America, Europe and select Asia-Pacific markets, offering both in-person workshops and online digital courses to help users build practical financial and business skills.
CTMX vs LGCY — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $19.2M |
| Net Profit | $-154.0K | $2.0M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 13.3% |
| Net Margin | -0.8% | 10.6% |
| Revenue YoY | -25.7% | 40.7% |
| Net Profit YoY | 97.6% | 46.0% |
| EPS (diluted) | — | $0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $19.2M | ||
| Q3 25 | — | $19.4M | ||
| Q2 25 | $18.7M | $18.0M | ||
| Q1 25 | $50.9M | $18.6M | ||
| Q4 24 | $38.1M | $13.6M | ||
| Q3 24 | $33.4M | $14.0M | ||
| Q2 24 | $25.1M | — | ||
| Q1 24 | $41.5M | — |
| Q4 25 | — | $2.0M | ||
| Q3 25 | — | $2.2M | ||
| Q2 25 | $-154.0K | $1.2M | ||
| Q1 25 | $23.5M | $2.8M | ||
| Q4 24 | $18.9M | $1.4M | ||
| Q3 24 | $5.7M | $2.1M | ||
| Q2 24 | $-6.5M | — | ||
| Q1 24 | $13.8M | — |
| Q4 25 | — | 13.3% | ||
| Q3 25 | — | 13.9% | ||
| Q2 25 | -6.9% | 11.1% | ||
| Q1 25 | 44.4% | 19.7% | ||
| Q4 24 | 46.4% | 12.2% | ||
| Q3 24 | 12.3% | 19.1% | ||
| Q2 24 | -33.7% | — | ||
| Q1 24 | 28.1% | — |
| Q4 25 | — | 10.6% | ||
| Q3 25 | — | 11.3% | ||
| Q2 25 | -0.8% | 6.8% | ||
| Q1 25 | 46.2% | 15.2% | ||
| Q4 24 | 49.6% | 10.3% | ||
| Q3 24 | 17.2% | 14.9% | ||
| Q2 24 | -26.0% | — | ||
| Q1 24 | 33.3% | — |
| Q4 25 | — | $0.15 | ||
| Q3 25 | — | $0.16 | ||
| Q2 25 | — | $0.07 | ||
| Q1 25 | — | $0.21 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $0.21 | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $21.1M |
| Total DebtLower is stronger | — | $660.3K |
| Stockholders' EquityBook value | $119.9M | $46.1M |
| Total Assets | $175.1M | $73.1M |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $21.1M | ||
| Q3 25 | — | $20.6M | ||
| Q2 25 | $49.0M | $20.3M | ||
| Q1 25 | $47.6M | $17.3M | ||
| Q4 24 | $38.1M | $16.9M | ||
| Q3 24 | $40.6M | $21.5M | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — |
| Q4 25 | — | $660.3K | ||
| Q3 25 | — | $776.9K | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | $1.0M | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | — | $758.2K | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $46.1M | ||
| Q3 25 | — | $43.7M | ||
| Q2 25 | $119.9M | $41.0M | ||
| Q1 25 | $25.0M | $39.3M | ||
| Q4 24 | $-456.0K | $36.4M | ||
| Q3 24 | $-23.5M | $32.6M | ||
| Q2 24 | $-31.2M | — | ||
| Q1 24 | $-31.7M | — |
| Q4 25 | — | $73.1M | ||
| Q3 25 | — | $72.1M | ||
| Q2 25 | $175.1M | $69.2M | ||
| Q1 25 | $98.5M | $67.1M | ||
| Q4 24 | $120.5M | $62.1M | ||
| Q3 24 | $139.0M | $50.6M | ||
| Q2 24 | $159.2M | — | ||
| Q1 24 | $184.7M | — |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.02× | ||
| Q2 25 | — | 0.03× | ||
| Q1 25 | — | 0.03× | ||
| Q4 24 | — | 0.03× | ||
| Q3 24 | — | 0.02× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $1.1M |
| Free Cash FlowOCF − Capex | $-15.8M | $512.7K |
| FCF MarginFCF / Revenue | -84.6% | 2.7% |
| Capex IntensityCapex / Revenue | 0.1% | 2.8% |
| Cash ConversionOCF / Net Profit | — | 0.52× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $4.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.1M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | $-15.8M | $3.0M | ||
| Q1 25 | $-21.0M | $918.7K | ||
| Q4 24 | $-19.9M | $659.0K | ||
| Q3 24 | $-20.7M | $3.2M | ||
| Q2 24 | $-19.5M | — | ||
| Q1 24 | $-26.0M | — |
| Q4 25 | — | $512.7K | ||
| Q3 25 | — | $809.7K | ||
| Q2 25 | $-15.8M | $2.9M | ||
| Q1 25 | $-21.2M | $596.6K | ||
| Q4 24 | $-20.0M | $466.8K | ||
| Q3 24 | $-20.7M | $2.9M | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
| Q4 25 | — | 2.7% | ||
| Q3 25 | — | 4.2% | ||
| Q2 25 | -84.6% | 16.2% | ||
| Q1 25 | -41.6% | 3.2% | ||
| Q4 24 | -52.5% | 3.4% | ||
| Q3 24 | -62.1% | 21.1% | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
| Q4 25 | — | 2.8% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | 0.1% | 0.5% | ||
| Q1 25 | 0.2% | 1.7% | ||
| Q4 24 | 0.2% | 1.4% | ||
| Q3 24 | 0.1% | 1.7% | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | 0.52× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 2.45× | ||
| Q1 25 | -0.89× | 0.33× | ||
| Q4 24 | -1.05× | 0.47× | ||
| Q3 24 | -3.61× | 1.52× | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
LGCY
Segment breakdown not available.
